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Abstract
Background: Glioma stem-like cells (GSCs) are proposed to be responsible for high resistance in glioblastoma
multiforme (GBM) treatment. In order to find new strategies aimed at reducing GSC stemness and improving GBM
patient survival, we investigated the effects and mechanism of a histone deacetylases (HDACs) inhibitor, suberoylanilide
hydroxamic acid (SAHA), since HDAC activity has been linked to cancer stem-like cell (CSC) abundance and properties.
Methods: Human GBM cell lines were plated in serum-free suspension cultures allowed for sphere forming and CSC
enrichment. Subsequently, upon SAHA treatment, the stemness markers, cell proliferation, and viability of GSCs as well
as cellular apoptosis and senescence were examined in order to clarify whether inhibition of GSCs occurs.
Results: We demonstrated that SAHA attenuated cell proliferation and diminished the expression stemness-related
markers (CD133 and Bmi1) in GSCs. Furthermore, at high concentrations (more than 5 μM), SAHA triggered apoptosis
of GSCs accompanied by increases in both activation of caspase 8- and caspase 9-mediated pathways. Interestingly, we
found that a lower dose of SAHA (1 μM and 2.5 μM) inhibited GSCs via cell cycle arrest and induced premature
senescence through p53 up-regulation and p38 activation.
Conclusion: SAHA induces apoptosis and functions as a potent modulator of senescence via the p38-p53 pathway in
GSCs. Our results provide a perspective on targeting GSCs via SAHA treatment, and suggest that SAHA could be used
as a potent agent to overcome drug resistance in GBM patients.
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Background
Glioblastoma multiforme (GBM) has a high recurrence
and mortality. The median survival time after a combin-
ation of radiotherapy and adjunct temozolomide (TMZ)
treatment is only about 14.6 months due to frequent
tumor relapse after surgical removal [1]. GBM tumor
cells are highly invasive, proliferate rapidly, and easily
display resistance to chemotherapy and irradiation. The
aggressiveness and high malignancy of GBM are linked
to an abundant source of glioma stem-like cells (GSCs)
[2]. Cancer stem-like cells (CSCs) are a small population
of cancer cells that possess the ability to self-renew and
are capable of inducing tumorigenesis [3]. The existence
of CSCs has been identified not only in the brain but
also in the breast, lung, and colon cancers [4]. GSCs are
considered responsible for resistance of GBM to chemo-
therapy and radiotherapy via their ability to activate the
cellular DNA damage response [5] and to resist
radiation-induced apoptosis through an increase in free
radical scavenging [6]. In order to develop novel, effi-
cient therapeutics against GBM, it is therefore important
not only to target GBM cancer cells but also to enhance
cytotoxicity of GSCs.
Histone deacetylases (HDACs) are overexpressed in a
wide variety of cancers [7], and recent studies indicated
that HDACs activities are required for maintaining CSC
in breast cancer and head and neck tumors [8, 9]. In
order to block their oncogenic potential in malignant
disease and their function in CSC, HDAC inhibitors are
considered to be applied in both experimental and clin-
ical settings. Suberoylanilide hydroxamic acid (SAHA), a
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HDAC inhibitor, has been shown to possess cytotoxicity
in various cancer cell-types such as T-cell lymphoma
[10], breast cancer [11], prostate cancer [12], and glio-
blastoma cells [10]. A previous study indicated that
SAHA elicits anti-cancer effects through the induction
of differentiation, apoptosis and cell cycle arrest [7].
However, the pharmacological effects of SAHA on CSCs
such as GSCs remain poorly understood.
Cellular senescence is a state of irreversible cell cycle
arrest evoked by several oncogenic stimuli. It includes a
tumor-suppressive mechanism [13]. Senescence in
tumor cells is usually associated with a DNA-damage re-
sponse and with tumor suppressor pathways such as
p53-p21 and p16-pRb [14]. p38 also plays an important
regulatory role in inducing cellular senescence, which
can be triggered by Ras-Raf activation, oxidative stress,
culture stress, or telomere shortening [15]. Furthermore,
p38 is shown to be important in mediating oncogene-
induced senescence in fibroblasts, indicating a role in
tumor suppression [16]. Replicative immortality, which
is one of the hallmarks of cancer, is also a potential
therapeutic target [17, 18]. Therefore, eliciting cellular
senescence or apoptosis could effectively repress immor-
tality of GBM cancer cells and may be important for
overcoming poor prognosis in GBM patients [19–21].
In this study, human GBM cells were plated in serum-
free suspension cultures allowed for GSC enrichment
[3, 22, 23]. We examined the effects of SAHA on cell
proliferation, viability, and stem cell-related markers
expression in GSCs. In addition, we studied GSCs reduc-
tion induced by SAHA through the mechanism of cellular
apoptosis and senescence by performing flow cytometry
analysis and senescence-associated β-galactosidase (SA-β-
gal) assay respectively. By examining the signaling path-
way, we further understood the mechanism of action of
SAHA. Our results show that SAHA is a potential candi-




Human glioblastoma U87MG and U373MG cells were
obtained from American type culture collection (ATCC).
Cells were cultured in Dulbecco’s Modified Eagle’s
medium (DMEM) (GIBCO, 12800-017) supplemented
with 10% FBS at 37 °C in a humidified atmosphere con-
taining 5% CO2. For sphere culture, cells were trypsi-
nized using 0.05% trypsin/EDTA and suspended at a
concentration of 1.6 × 105 cells in 6-cm dishes pre-
coated with poly-(2-hydroxyethyl methacrylate) (poly-
HEMA) for 2–14 days. The cells were cultured in
serum-free DMEM/F12 (GIBCO, 12500-062) containing
10 ng/ml EGF (Invitrogen, PHG0311), 10 ng/ml FGF
(Invitrogen, PHG0263) and N-2 supplement (GIBICO,
17502-048). After spheroid formation, the spheres were
pre-incubated with or without 3 μM SB203580 for 1 h
and treated with different doses of SAHA for various
time intervals as described in figure legends. The
morphology of spheroid bodies was observed using light
microscopy.
Chemicals and antibodies
SAHA was synthesized by Prof. J. P Liou in Taipei
Medical University [24] and was dissolved in dimethyl-
sulfoxide (DMSO) (Fisher Scientific, 67-68-5). SB203580,
a specific p38 inhibitor, was purchased from Selleckchem
(S1076) and dissolved in DMSO. The following com-
mercial antibodies were used in Western blotting and
Immunofluorescence: CD133 (Proteintech, 18470-1-
AP), Bmi1 (GeneTex, GTX114008), Nanog (GeneTex,
GTX100863), Oct3/4 (Santa Cruz, SC5279), Vimentin
(GeneTex, GTX100619), Sox2 (GeneTex, GTX101507),
tubulin (Proteintech, 66031-1-lg), PARP (Cell Signaling,
9542S), caspase-8 (GeneTex, GTX110723), caspase-9 (Cell
Signaling, 9502S), caspase-3 (Cell Signaling, 9661S), cyclin
B1 (Santa Cruz, SC245), CDK1 (Santa Cruz, SC8395), p21
(Cell Signaling, 2947S), PCNA (Cell Signaling, 2586S),
Phospho-p38 (p-p38, T180/Y182) (Cell Signaling, 9211S),
p38 (Cell Singling, 8690S), p53 (Cell Signaling, 2524S),
Phospho-p53 (Ser15) (Cell Signaling, 9284S), Phospho-
p53 (Ser33) (Cell Signaling, 2526S), and Alexa Fluor 594-
conjugated goat anti-rabbit IgG polyclonal antibodies
(Invitrogen, A-11037).
MTT viability/proliferation assay
Cells or dissociated spheroids by trypsin/EDTA were
incubated with fresh medium containing MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
reagent (final concentration of 0.5 mg/ml, Bionovas,
AM0815-0001) for 1 h at 37 °C. After incubation, the
MTT solution was removed and the resultant formazan
crystals were dissolved in 200 μl DMSO. The absorbance
readings of DMSO extracts were measured at 570 nm
using the iMark Microplate Absorbance Reader (Bio-Rad).
Western blotting analysis
GSCs were lysed using modified RIPA buffer (50 mM
Tris-HCl pH 7.8, 150 mM NaCl, 15 mM EDTA, 0.5%
Triton X-100, 0.5% Nonidet P-40 and 0.1% sodium
deoxycholate) containing a protease inhibitor cocktail
(Roche, 04693116001). The lysates were centrifuged at
13,200 rpm for 20 min at 4 °C and supernatants were
collected for quantification of proteins by Micro BCA
Protein Assay Kit (Thermo scientific, 23235). Equal
amounts of proteins from each sample (10–20 μg) were
separated by 10–12% SDS-PAGE and transferred onto a
PVDF membrane (Bio-RAD, 162-0177). The membrane
was blocked with TBST buffer containing 5% nonfat
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milk, and then was incubated overnight with appropriate
primary antibodies at 4 °C. Finally, the membranes were
incubated with horseradish peroxidase-conjugated sec-
ondary antibodies. Proteins were detected using an ECL
kit (GE Healthcare, RPN2106) and visualized on a Kodak
autoradiography film.
Immunofluorescence analysis
Cells were fixed with 4% paraformaldehyde for 20 min,
blocked with 1% BSA in PBS for 1 h, and incubated with
1:100-diluted primary antibodies for 4 h at 4 °C. Next,
the cells were washed with PBS and incubated with
1:200-diluted Alexa Fluor 594-conjugated second anti-
bodies for 1 h at 4 °C. Finally, the cells were mounted in
glycerol containing 4’-6-diamidino-2-phenylindole (DAPI),
and examined using a fluorescence microscope (Leica
STP6000).
Senescence-associated β-galactosidase (SA-β-gal) assay
Spheroid GSCs were fixed with 1× fixation buffer pro-
vided in an SA-β-gal assay kit (Cell signaling, 9860) for
10–15 min. After fixation, the cells were centrifuged at
800 rpm at room temperature for 3 min, following by
manufacturer’s guidelines. For each condition, three
bright-field micrographs were captured and counted in
three randomly chosen fields. All cultures were per-
formed in triplicate and represented by three independ-
ent experiments.
Soft agar colony formation assay
To examine anchorage-independent growth, trypsinized
spheres (2 × 104 cells/ml) were suspended in 0.4%
SeaKem LE Agarose (Lonza, 50004) with serum-free
DMEM/F12 containing 10 ng/ml EGF, 10 ng/ml FGF
and N-2 supplement. This suspension formed the upper
layer, which was poured onto a lower layer formed of
0.8% agarose in a composition otherwise identical to
the upper layer. The layers with the cell suspension
were poured into 6-well plates. The cells were incu-
bated at 37 °C in a 5% CO2 atmosphere. After 14–
30 days, the cells were stained with 0.05% crystal vio-
let, and the colonies were photographed and counted
in three randomly chosen fields. All cultures were
performed in triplicate and represented by three inde-
pendent experiments.
Annexin V-PI staining
The spheres were centrifuged at 800 rpm for 3 min
and trypsinized with 0.05% trypsin/EDTA in order to
resuspend them. An FITC Annexin V Apoptosis
Detection Kit (BD Pharmingen, 556547) was employed
according to the manufacturer’s guidelines. Flow cytom-
etry was carried out using a BD FACSCalibur Flow
Cytometer.
Real-time PCR
Total RNA was isolated by TRIzol (Thermo Fisher
Scientific, 15596026), and 3 μg of total RNA were sub-
jected to SuperScript II Reverse Transcriptase PCR
(Thermo Fisher Scientific, 18064014). The expression of
p53 mRNA was determined using 2 × SYBR real time
master mix (Applied Biosystems) and primers specific to
p53 (F: 5'- CTTTGAGGTGCGTGTTTGTG; R: 5'-
GTGGTTTCTTCTTTGGCTGG), or the control gene
GAPDH (F: 5’- GAAGGTGAAGGTCGGAGTC; R: 5’-
GAAGATGGTGATGGGATTC). SYBR green fluores-
cence was then monitored using an ABI 7000 Sequence
Detection System (Applied Biosystems).
Statistical analysis
The data collected from each experiment, containing
both experimental and control groups, were reported as
means while error bars represent the standard deviation
(S.D.). One-way analysis of variance and an unpaired
Student’s t-test were performed to analyze the differ-
ences between groups using the GraphPad Prism 5 pro-
gram. *, P < 0.05; **, P < 0.01 are considered statistically
significant. The quantification of protein expression was
done using band analysis tools in imageLab software
5.2.1 (Bio-RAD). The band intensities obtained from
Western blotting were quantified by subtracting back-
ground density and normalizing against the loading
control.
Results
SAHA suppresses cell viability/proliferation and stemness-
related markers in GSCs
To elucidate the effects of SAHA on GSCs, we used
sphere cultures to induce spheroid bodies formation
from U87MG (Fig. 1a) and U373MG (Additional file 1:
Figure S1A) GBM cells, since a spheroid environment
can be employed to enrich CSCs [25, 26]. After 2–
14 days of incubation, stem cell-related properties in the
spheroids were further examined via stemness-related
markers, such as CD133, Bmi1, Nanog, Oct3/4, and
Sox2. As shown in Fig. 1b to d and Additional file 1:
Figure S1B, the formation of spheroids was in accord-
ance with increased stemness-related protein expression,
accompanied by a decrease in astrocyte markers
(Vimentin) (Fig. 1d). The spheres were then reattached
to plates in serum-containing medium to induce cellular
differentiation (Fig. 1e), resulting in decreased levels of
stem cell-related markers and an increase in Vimentin
(Fig. 1d). Furthermore, we examined tumor proliferation
at limiting cell numbers (3 x 102 cell per well) between
U87MG adherent cells and spheroids. The result as
shown in Fig. 1f demonstrated sphere cells displayed
high levels of proliferation potential. Since stem cells are
defined as being capable of both self-renewal and
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differentiation, we further studied generation of the sec-
ondary spheres from a single U87MG GSC, as well as
induced cell differentiation after the spheroid body for-
mation. As shown in Fig. 1g and h, a single cell from
spheroids was able to generate a new sphere and to dif-
ferentiate into more mature GBM cells. These findings
indicate the GBM sphere cells with the stemness-related
properties.
We subsequently investigated the effects of SAHA on
GBM adherent cells and GSCs, and results showed that
SAHA treatment appeared to significantly inhibit cell
viability in both adherent and GSCs (Fig. 2a, b and
Additional file 1: Figure S1C, 1D) as well as to suppress
cell growth and sphere formation (Fig. 2c and d). Add-
itionally, since colony formation of single cell by growth
in soft agar is indicated reflecting the self-renewing cap-
acity of CSCs [27], we performed a soft agar assay to fur-
ther examine the effects of SAHA on clonogenicity of
GSCs. As expected, SAHA was found to suppress colony
formation of cells from dissociated GSCs in a dose-
dependent manner (Fig. 2e and f). Furthermore,
stemness-related markers such as CD133 and Bmi1 were
also decreased by SAHA (Fig. 2g and h). Altogether,
the findings suggest that ell viability/proliferation and
Fig. 1 Serum-free suspension culture induces the enrichment of Glioma stem-like cells (GSCs). a and b GSCs from U87MG GBM cells were grown
in serum-free DMEM/F12 medium/suspension culture for 2–14 days. Sphere morphology (2 weeks) was photographed by light microscopy and
spheroids (2–14 days) were harvested and subjected to Western blotting using indicated antibodies. c The protein expression levels were
quantified by imageLab software 5.2.1 (Bio-RAD). The protein expression of U87MG parental (Adherent) was defined as 1 and other values were
accordingly normalized. d and e U87MG spheres were reattached to without poly-HEMA-coated plates in a serum-containing medium for 1 day,
in order to induce GSCs differentiation. The levels of stem cell-related markers and Vimentin, an astrocytic marker, in parental cells (Adh), GSCs
(Sph), and differentiated GSCs (Dif) were measured via Western blot with antibodies as indicated (d). Representative images are shown in (e). f
U87MG adherent cells and dissociated spheroids by trypsin/EDTA were plated at a density of 3 x 102 cells/well. After 0, 3, 6, and 9 days of culture,
cell proliferation capacity was determined by using MTT assay. Bar graphs represent means ± standard errors of the means (SEM) from three
independent experiments (t-test: *p < 0.05; **p < 0.01). g A single cell isolated from primary spheroids was cultured in a 96-well dish. The propagation
of a secondary spheroid formation was recorded at day 0, 3, and 6, separately (upper panels). Subsequently, this secondary spheroid was reattached to
plates to induce cellular differentiation (lower panel). h Immunofluorescence images of CD133 staining in the secondary spheroid and differentiated
cells. The nuclei were stained with DAPI (blue)
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stemness-related features of GSCs are suppressed by
treatment with SAHA.
SAHA induces apoptosis in U87MG GSCs
To clarify the mechanism by which SAHA treatment at-
tenuates growth and viability of GSCs, we examined
whether SAHA induces programmed cell death. Flow
cytometry with propidium iodide (PI) staining was per-
formed, and the results indicated that the sub-G1 popu-
lation representing apoptotic cells was increased in
response to 2.5 μM, 5 μM, 10 μM and 25 μM of SAHA
treatment (Fig. 3a and c). Moreover, SAHA-induced
apoptosis in GSCs was further confirmed using the
Annexin V/PI assay. Both early (Annexin V positive and
PI negative) and late (Annexin V and PI positive) apop-
tosis populations were increased upon SAHA treatment
in a dose-dependent manner (Fig. 3b and d). Further-
more, the cleaved proteins of apoptosis-related markers
were measured by Western blotting. The results, shown
in Fig. 3e, revealed that SAHA induced the accumulation
of activated caspases and cleaved PARP. However, a fur-
ther experiment conducted using a pan caspase inhibitor
Z-VAD-FMK to reduce caspases activation in GSCs re-
sulted in inhibition of SAHA-induced cell death (Fig. 3f
and g). In summary, we confirmed that SAHA simultan-
eously inhibits cell viability and induces apoptosis at
both early and late phases in GSCs.
SAHA at a low concentration leads to cell cycle arrest in
GSCs
As shown in Fig. 2, SAHA at a low concentration
(2.5 μM) reduced stemness-related markers levels and
Fig. 2 SAHA suppresses cell viability and diminishes the expression stemness-related markers in GSCs. a and b U87MG adherent cells and spheroids
were treated with DMSO or different doses of SAHA (0, 3, 6 μM) for various time intervals (1 to 6 days). After treatment, cell viability was assessed using
colorimetric MTT assay. c U87MG spheroids were treated with different doses of SAHA as indicated for various time intervals (0, 1, 2, 3 days). After
treatment, the cell proliferation was examined by performing cell counting (Trypan blue exclusion) assay. d Photomicrographs of GSCSs treated with
different dosages of SAHA were randomly selected in microscopic fields. e and f Cells from dissociated GSCs via trypsinization were grown in soft agar
followed by treatment with SAHA at different doses every 48 h. After 14–30 days of incubation at 37 °C, colonies arose from these single cells were
photographed randomly and counted in the three fields chosen. The histogram of average colony numbers was obtained by performing
the experiment in triplicate; bar, S.D.; *p < 0.05; **p < 0.01. g and h GSCs after 48 h of SAHA treatment were harvested and the protein
expression levels of stemness markers were analyzed by Western blotting with indicated antibodies. The protein levels were quantified by
imageLab software 5.2.1 (Bio-RAD)
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colony formation, but did not significantly increase
apoptotic markers and sub-G1 population in GSCs
(Fig. 3). Therefore, we speculate that treatment with a
low concentration SAHA causes GSC growth arrest. We
assessed the cell cycle of GSCs by flow cytometry, and
the results indicated that low doses (1 μM and 2.5 μM)
of SAHA caused a decrease in the proportion of S and
G2/M cells and a corresponding increase in cells with a
DNA content greater than 4 N (Fig. 4a and b). Addition-
ally, the G1 cells were slightly increased in SAHA treat-
ment compared to DMSO-treated controls (Fig. 4a).
After finding the significant decrease of the G2/M popu-
lation, we further examined the expression of G2/M-
regulated factors, such as cyclin B1 and CDK1. Their
expression levels were significantly downregulated
(Fig. 4c). Subsequently, we also found the elevation of
p21 and the reduction of PCNA, which may relate to
a slight increase in G1 cells and a decrease in S cells
respectively after SAHA treatment (Fig. 4c). These re-
sults show that SAHA at low concentrations does not
trigger apoptosis but interrupts cell cycle progression
leading to an increase in polyploid and/or G1 cells in
GSCs.
Low concentrations of SAHA induce premature
senescence in GSCs via p38 activation
Since progressive accumulation of G1 tetraploidy or
polyploidy is a unique senescence phenotype [28], we
Fig. 3 SAHA induces apoptosis in GSCs. a and b GSCs from U87MG cells were treated with different doses of SAHA as indicated for 2 days. After
treatment, cells were stained with PI alone (a) and with both FITC Annexin V and PI (b), and apoptotic cell death was measured using flow
cytometry. c and d Percentage of sub-G1, early and late apoptotic cells. Data are presented as mean ± S.D. for experiments performed in triplicate;
bar, S.D. e Expression of cleaved-caspase-8, −caspase-3, and -PARP as well as pro-caspase-9 were determined by Western blotting. f and g GSCSs
were treated with 25 μM SAHA alone, 20 μM Z-VAD-FMK (Caspase Inhibitor) alone, or SAHA + Z-VAD-FMK for 48 h, following which cell lysates
were analyzed via Western blot with indicated antibodies (f). g Cell viability was also assessed using MTT assay. Bar graphs represent means ± SEM from
three independent experiments (t-test: **p < 0.01)
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investigated whether premature senescence was induced
by SAHA treatment. By examining the signals involved
in regulation of cellular senescence, we verified that
levels of p53 protein and p38 phosphorylation were up-
regulated 7 days after SAHA treatment in a dose-
dependent manner (Fig. 5a). Subsequently, we measured
the activity of SA-β-gal, which is a direct marker of cel-
lular senescence. We found that GSCs displayed high
SA-β-gal activity upon SAHA treatment (Fig. 5b), and
the quantification of SA-β-gal positive cells using light
microscopy showed about 70% of spheroid bodies be-
coming senescent (Fig. 5c). The activated p38 signaling
pathway has been shown to be responsible for senes-
cence induction in the past [15, 29]. To investigate
whether SAHA triggers cellular senescence via p38 acti-
vation, we used a p38-specific inhibitor, SB203580, and
found that pre-treatment with SB203580 resulted in at-
tenuation of SAHA-induced SA-β-gal activity (Fig. 5d
and e). Furthermore, low-dose SAHA-elicited phosphor-
ylation of p38 at Thr180/Tyr182, phosphorylation of p53
at Ser33, and p53 protein levels were also significantly
attenuated by SB203580 (Fig. 5f and g). To examine cel-
lular apoptosis by the detection of caspase-3 activity, we
found that low doses of SAHA didn’t correlate with
apoptosis occurrence (Fig. 5g and h). However, the treat-
ment of short-term and high-dose SAHA induced p53
phosphorylation at Ser15 instead of Ser33 as well as
caspase-3 activation (Fig. 5h). These results demonstrate
that p38-mediated activation of p53 through phosphoryl-
ation at Ser33 is essential for low-dose SAHA-induced
senescence in GSCSs, but not affecting high-dose
SAHA-induced cell death.
Discussion
The clinical treatment of GBM usually begins with sur-
gery, followed by radiation therapy and chemotherapy.
However, the median time of survival for GBM patients
is only about 1 year and the 5-year survival rate is less
than 5% [30]. An abundance of CSCs may contribute to
the therapeutic resistance of GBM and a consequently
high mortality rate [2, 5, 31, 32]. As shown in Additional
file 1: Figure S2, the result of immunohistochemistry
staining verified that the stemness proteins CD133 and
Bmi1 were indeed increased in TMZ-resistant tumors in
xenograft models. In order to reduce therapeutic resist-
ance, development of a novel drug targeting GSCs is
Fig. 4 SAHA causes cell cycle arrest of GSCs. a GSCs from U87MG cells were treated with SAHA (1 μM and 2.5 μM) for 24 h. The spheres were
harvested for PI staining and analyzed by using flow cytometry. b Data regarding the population of sub-G1, G1, S, G2/M and > 4 N upon SAHA
treatment was presented as the mean ± S.D. of experiments performed in triplicate; bar, S.D.; *p < 0.05, **p < 0.01. c The expression levels of cyclin
B1, CDK1, PCNA, and p21 were measured by Western blotting. Tubulin was used as a loading control
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important. In our study, we used sphere cultures-
induced GSCs and found that SAHA treatment inhibited
cell viability/proliferation and stemness-related markers
expression in GSCs. Although several studies have dem-
onstrated that caspase-dependent apoptosis is an effect-
ive strategy for treating GBM, it has been proven that
malignant gliomas develop anti-apoptosis mechanisms
to escape tumor cell death [33, 34]. Interestingly, our
study revealed that SAHA not only induced apoptotic
cell death at higher doses but also induced senescence in
GSCs at low concentrations (Fig. 6). Additionally, previ-
ous studies indicate that SAHA treatment has some side
effects including nausea, vomiting, diarrhea, and anemia
[35–37]. To relieve these side effects, a reduced dosage
of SAHA treatment is necessary. Altogether, we demon-
strated that SAHA inhibits GSCs via different mechanisms
at high and low doses. Moreover, and more importantly, a
restriction of GSCs at lower doses of SAHA might indi-
cate potential for administration of SAHA, and it may de-
crease uncomfortable side effects in patients.
Self-renewal in CSCs fuels tumor growth and provides
the maintenance of stemness in a small population of
cancer cells [3, 38]. If a therapeutic treatment eliminates
the non-self-renewing cells, but not the CSCs. In this
case, the tumor would shrink, but it would return form
the remained CSCs when the therapy is stopped. There-
fore, preventing drugs resistance and self-renewal in
GSCs are important to avoid GBM recurrence. As
shown in Fig. 2, we found that GSCs were inhibited
upon SAHA treatment, suggesting that SAHA may over-
come therapeutic resistance in GBM by targeting GSCs.
Furthermore, the marker Bmi1 is an important factor for
the self-renewal and stemness maintenance of CSCs
[39]. This suggests that targeting Bmi1 may be an effi-
cient way to prevent cancer recurrence. As shown in
Fig. 2, SAHA significantly suppressed Bmi1 expression
in a dose-dependent manner, implying that SAHA in-
hibits GSCs by blocking the self-renewal mechanism. In
addition, we have examined the viability between
U87MG adherent cells and U87MG spheroids by per-
forming MTT assay, and verified SAHA at higher doses,
primarily induces apoptosis, leading to inhibition of cel-
lular proliferation in both cells (Fig. 2a and b). Interest-
ingly, at low-dose treatment of SAHA (1 μM), only
spheroids were inhibited well up to 6 days after treat-
ment comparing with U87MG adherent cells. The result
implies that GSCs are sensitive to SAHA-induced
senescence.
Fig. 5 SAHA induces GSCs senescence via activation of the p38-p53 pathway. a to c GSCs from U87MG cells were collected 7 days after
treatment of SAHA at different doses. The cellular lysates were then analyzed by Western blotting with indicated antibodies (a). The
senescence-associated β-galactosidase (SA-β-gal) activities were then examined by SA-β-gal kit (Cell Signaling, details described in materials
and methods). Photomicrographs of spheroid bodies were randomly selected in microscopic fields (b) and the percentage of SA-β-gal positive
cells was quantified; bar, S.D.; ** p < 0.01 (c). d to g GSCs were pre-treated with or without 3 μM SB203580 (SB) for 1 h and then treated with
DMSO or with SAHA (1 μM in G, 2.5 μM in d to g) for 7 days. After treatment, cellular senescence was measured by the detection of SA-β-gal
activity (d). The percentage of SA-β-gal positive cells was quantified; bar, S.D., *, P < 0.05, **, P < 0.01 (e). The protein lysates were analyzed by
Western blotting with indicated antibodies (f and g). h GSCSs were treated with DMSO or with different doses of SAHA as indicated for 2 days.
After treatment, the protein lysates were analyzed by Western blotting
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Previous study indicated that p53 plays an essential
role in SAHA-induced apoptosis in MCF-7 cells [40],
whereas other studies suggested that SAHA shows pref-
erential cytotoxicity in several p53-mutant cancer cells
through inhibition of the HDAC6-Hsp90 chaperone axis
[41], indicating the complexity of mechanism by which
SAHA medicates apoptosis in wild type and p53-
deficient tumors. In cancer stem cell-like spheroids, we
found that both levels of p53 protein and its phosphoryl-
ation at Ser15, but not at Ser33, were increased within
2 days after treatment with high doses (10 μM and
25 μM) of SAHA (Fig. 5h). Especially, these doses of
SAHA triggered significant apoptosis in U87MG (p53wt)
GBM cells (Fig. 3b). When we further used another
malignant GBM cell line, U373MG that expresses
mutant p53 protein (R273H mutation, p53R273H),
however, a high-dose SAHA (10 μM) inhibited cell
viability in U373MG spheroids as well (Additional file 1:
Figure S1). These results indicated that SAHA indu-
cing cell death in cancer cells and even in cancer
stem cell-like spheroids might be through both p53-
dependent and p53-independent apoptosis pathways.
A recent study further investigated the mechanism of
SAHA-induced apoptosis in couple leukemic cell
lines, HL-60 (p53null) and CML-T1 (p53wt) [42].
While leukemic cells were treated with combination
of SAHA and decitabine (DAC), a methyltransferase
inhibitor, p53-dependent apoptosis is triggered by the
upregulation of Puma and p21 in CML-T1 cells, and
p53-independent apoptosis is triggered by inhibition
of survivin and upregulation of p21 in HL-60 cells.
Although this study probably explained the different
mechanisms of SAHA-induced cell death between
p53null and p53wt cancer cells, in GSCs the roles of
p53 after SAHA treatment remains unclear and needs
further studies.
Since many post-translational modifications report-
edly modulate protein stabilization and transcriptional
activation of p53 [43], the rigorous control of these
modifications on p53 may determine its functional
role under several stresses. Various p53 residues can
be phosphorylated by different kinases. For example,
phosphorylation at Ser 6, 9, and 15, is carried out by
ATM, occurs in response to genotoxic stresses, espe-
cially Ser15 of p53 is rapidly phosphorylated after
stress in order to represent a priming event for the
subsequent series of modifications [44], such as Ser20
phosphorylation by Chk2 and C-terminal acetylation
by p300, CBP and P/CAF. Then these secondary
modifications prevent the degradation of p53 and in-
crease its apoptotic induction [43, 45]. Furthermore,
stressful situations may also elevate p53 phosphoryl-
ation at Ser33, by p38 kinase, and at Thr81, by JNKs
kinase, all of which are present in Ser/Thr–Pro motifs.
These phosphorylated motifs lead to p53 interacting
with Pin1 which in turn induces proline isomerization
in p53 [46]. Such conformational changes have in-
tense effects on p53 transcriptional activity and pro-
tein stability and shows an increase in cell cycle
checkpoint activation following genotoxic stress. There-
fore, it is evident that only a number of stress-responsive
kinases alter p53 at exact sites which recruits Pin1
Fig. 6 A diagram illustrates the signaling mechanisms of how SAHA may be inhibiting GSCs. Low-dose of SAHA increases both p53 protein and
its phosphorylation at Ser33 via p38 activation, leading to a rise in cell cycle checkpoint activation and cellular sensecence, but high-dose of SAHA
induces p53 Ser15 phosphorylation and caspase-mediated involving both the caspase-8 and the caspase-9 pathways in GSCs
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interaction in order to complete an additional step in the
process of activation.
When we treated GBM stem cell-like spheroids with
low doses of SAHA (1 μM and 2.5 μM), we found that
both p53 protein and its phosphorylation at Ser33 were
slight increased on 2 days after SAHA treatment, but
they were risen significantly after 1 week of treatment
(Fig. 5g and h). However, pharmacological inhibition of
p38 kinase attenuated p53 accumulation and its phos-
phorylation at Ser33, which resulted in a reduction in
the senescent phenotype (Fig. 5d to g). In addition, we
observed that low doses of SAHA-induced phosphory-
lated p53 at Ser33 didn’t seem to correlate with apop-
tosis occurrence by the detection of caspase-3 activity
(Fig. 5g and h). Therefore, we summarized the results re-
vealing that low-dose and long-term treatment with
SAHA in GBM spheroids induces p53 phosphorylation
at Ser33 causing an increase in cell cycle checkpoint ac-
tivation (Fig. 6), but SAHA in high-dose and short-term
treatment induces p53 phosphorylation at Ser15 leading
to p53-dependent apoptosis in U87MG spheroids, and
even induces p53-independent apoptosis in U373MG
spheroids (Fig. 6).
To further understand the regulated mechanism of
p53 after SAHA treatment, Real-time PCR was per-
formed and the result showed a slight increase in p53
mRNA levels after low concentrations treatment of
SAHA, but no change at a high-dose (10 μM) treatment
(Additional file 1: Figure S3). Combining with the
reason that phosphorylation of p53 at multiple sites,
including Ser15, Ser20, and Ser33, can protect its pro-
tein stability against MDM2-mediated ubiquitination
and degradation [43], we think that low-doses SAHA
might alter the transcriptional activity and protein
stability to trigger p53 up-regulation, but high-doses
SAHA rise p53 levels primarily by preventing the pro-
tein degradation.
Cellular senescence is a tumor-suppressive mechan-
ism leading to permanent cell cycle arrest. Although
SAHA-induced polyploidy, resulting in loss of prolif-
eration and commitment to senescence, has been
demonstrated in human colon cancers and breast
cancer cells [47], the effects and molecular mecha-
nisms of SAHA in CSCs remained unclear. In our
study, we clarified that a reduced dose of SAHA not
only increases polyploidy but also decreases S and
G2/M cells in GSCs, indicating that SAHA induces
GSCs senescence by blocking cell cycle progression as
well as via polyploid cell accumulation. Previous study
indicated that Cyclin A1 is a p53-induced gene that
mediates cycle arrest and polyploidy [48]. Addition-
ally, we used a p38 inhibitor to demonstrate that
p38-regulated p53 phosphorylation at Ser33, affecting
p53 transcriptional activation and protein accumulation, is
essential for SAHA-induced GSC senescence. Crucially,
SAHA has been determined capable of crossing the
blood-brain barrier at micromolar concentrations [49, 50].
Taken together, the evidence suggests that at lower doses,
SAHA may be used as a drug targeting CSCs through the
induction of senescence, helping to overcome drug resist-
ance in GBM.
Conclusions
We demonstrated that SAHA suppressed cell prolifera-
tion and diminished stemness properties in GSCs. Ad-
ministration of high concentrations of SAHA triggered
apoptosis of GSCs accompanied by increases in both ac-
tivation of caspase 8- and caspase 9-mediated pathways.
Interestingly, we found that SAHA at a low dose led to
cell cycle arrest in GSCs via upregulation of p21, and in-
duced premature senescence through activating p38/p53
pathway. Our results provide a perspective on targeting
GSCs via SAHA treatment, and suggest that SAHA
could be used as a potent agent to overcome drug resist-
ance in GBM patients.
Additional file
Additional file 1: Supplementary information includes Figures S1 to S3
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